Targeting of Insulin-Like Growth Factor Type 1 Receptor in Ewing Sarcoma: Unfulfilled Promise or a Promising Beginning?

par Ho, Alan L., Schwartz, Gary K.
Publié 2011

The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

par Nair, Jayasree S, Ho, Alan L, Schwartz, Gary K
Publié 2012

Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on (18)F-FDG PET/CT

par Krebs, Simone, Petkovska, Iva, Ho, Alan L., Ulaner, Gary A.
Publié dans Clin Nucl Med (2020)

Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy

par Samstein, Robert M., Ho, Alan L., Lee, Nancy Y., Barker, Christopher A.
Publié 2014

Androgen Receptor Signaling in Salivary Gland Cancer

par Dalin, Martin G., Watson, Philip A., Ho, Alan L., Morris, Luc G. T.
Publié dans Cancers (Basel) (2017)

Correlation of BRAF(V600E) Mutation and Glucose Metabolism in Thyroid Cancer Patients: An (18)F-FDG PET Study

par Nagarajah, James, Ho, Alan L., Tuttle, R. Michael, Weber, Wolfgang A., Grewal, Ravinder K.
Publié dans J Nucl Med (2015)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

par Ho, Alan L., Musi, Elgilda, Ambrosini, Grazia, Nair, Jayasree S., Deraje Vasudeva, Shyamprasad, de Stanchina, Elisa, Schwartz, Gary K.
Publié 2012

Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780

par Nair, Jayasree S., Ho, Alan L., Tse, Archie N., Coward, Jesse, Cheema, Haider, Ambrosini, Grazia, Keen, Nicholas, Schwartz, Gary K.
Publié 2009

PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma

par Ho, Alan L., Vasudeva, Shyamprasad Deraje, Laé, Marick, Saito, Tsuyoshi, Barbashina, Violetta, Antonescu, Cristina R., Ladanyi, Marc, Schwartz, Gary K.
Publié 2012

Phase II study of VEGF trap for the treatment of metastatic thyroid cancer

par Sherman, Eric J., Dunn, Lara, Ho, Alan L., Baxi, Shrujal, Ghossein, Ronald A., Haque, Sofia, Sima, Cami, Tuttle, Robert Michael, Pfister, David G.
Publié dans Cancer (2019)

A Phase 1 Study of Everolimus Plus Docetaxel Plus Cisplatin as Induction Chemotherapy for Patients With Locally and/or Regionally Advanced Head and Neck Cancer

par Matthew G., Fury, Sherman, Eric, Ho, Alan L., Xiao, Han, Tsai, Frank, Oby, Nwankwo, Sima, Camelia, Heguy, Adrian, Katabi, Nora, Haque, Sofia, Pfister, David G.
Publié 2013

Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma

par Tchekmedyian, Vatche, Sherman, Eric J., Dunn, Lara, Tran, Crystal, Baxi, Shrujal, Katabi, Nora, Antonescu, Cristina R., Ostrovnaya, Irina, Haque, Sofia S., Pfister, David G., Ho, Alan L.
Publié dans J Clin Oncol (2019)

Phase II Study Evaluating the Combination of Sorafenib and Temsirolimus in the Treatment of Radioactive Iodine-Refractory Thyroid Cancer

par Sherman, Eric J., Dunn, Lara, Ho, Alan L., Baxi, Shrujal, Ghossein, Ronald A., Fury, Matthew G., Haque, Sofia, Sima, Cami, Cullen, Grace, Fagin, James, Pfister, David G.
Publié dans Cancer (2017)

Sex Disparities in Salivary Malignancies: Does Female Sex Impact Oncological Outcome?

par Mimica, Ximena, McGill, Marlena, Hay, Ashley, Zanoni, Daniella Karassawa, Shah, Jatin P., Wong, Richard J., Ho, Alan L., Cohen, Marc A., Patel, Snehal G., Ganly, Ian
Publié dans Oral Oncol (2019)

Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers

par Untch, Brian R., Anjos, Vanessa Dos, Garcia-Rendueles, Maria E.R., Knauf, Jeffrey A., Krishnamoorthy, Gnana P., Saqcena, Mahesh, Bhanot, Umeshkumar K., Socci, Nicholas D., Ho, Alan L., Ghossein, Ronald, Fagin, James A.
Publié dans Cancer Res (2018)

The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype

par Linxweiler, Maximilian, Kuo, Fengshen, Katabi, Nora, Lee, Mark, Nadeem, Zaineb, Dalin, Martin G., Makarov, Vladimir, Chowell, Diego, Dogan, Snjezana, Ganly, Ian, Hakimi, A. Ari, Wong, Richard J., Riaz, Nadeem, Ho, Alan L., Chan, Timothy A., Morris, Luc G.T.
Publié dans Clin Cancer Res (2020)

Tipifarnib in Recurrent, Metastatic HRAS-Mutant Salivary Gland Cancer

par Hanna, Glenn J., Guenette, Jeffrey P., Chau, Nicole G., Sayehli, Cyrus M., Wilhelm, Christian, Metcalf, Robert, Wong, Deborah J., Brose, Marcia, Razaq, Mohammad, Pérez-Ruiz, Elisabeth, Cohen, Ezra E. W., Aggarwal, Rahul, Scholz, Catherine, Gualberto, Antonio, Ho, Alan L.
Publié dans Cancer (2020)

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences From Central Serous Chorioretinopathy

par Francis, Jasmine H, Habib, Larissa, Abramson, David H, Yannuzzi, Lawrence A, Heinemann, Murk, Gounder, Mrinal M, Grisham, Rachel N, Postow, Michael A, Shoushtari, Alexander N, Chi, Ping, Segal, Neil H, Yaeger, Rona, Ho, Alan L, Chapman, Paul B, Catalanotti, Federica
Publié dans Ophthalmology (2017)

The Repertoire of Genetic Alterations in Salivary Duct Carcinoma Including a Novel HNRNPH3-ALK Rearrangement

par Dogan, Snjezana, Ng, Charlotte K.Y., Xu, Bin, Kumar, Rahul, Wang, Lu, Edelweiss, Marcia, Scott, Sasinya N., Zehir, Ahmet, Drilon, Alexander, Morris, Luc G.T., Lee, Nancy Y., Antonescu, Cristina R., Ho, Alan L., Katabi, Nora, Berger, Michael F., Reis-Filho, Jorge S.
Publié dans Hum Pathol (2019)

Sustained ERK inhibition maximizes responses of Braf(V600E) thyroid cancers to radioiodine

par Nagarajah, James, Le, Mina, Knauf, Jeffrey A., Ferrandino, Giuseppe, Montero-Conde, Cristina, Pillarsetty, Nagavarakishore, Bolaender, Alexander, Irwin, Christopher, Krishnamoorthy, Gnana Prakasam, Saqcena, Mahesh, Larson, Steven M., Ho, Alan L., Seshan, Venkatraman, Ishii, Nobuya, Carrasco, Nancy, Rosen, Neal, Weber, Wolfgang A., Fagin, James A.
Publié dans J Clin Invest (2016)